BioMedNewsBreaks

FridayMar 12, 2021 11:52 am

BioMedNewsBreaks – United Medical Equipment Business Solutions Network Inc. Poised to Play Key Role in Fast Tracking Economic Revival

United Medical Equipment (“UME,” “UMEBSNI”), a supplier of both antigen and antibody COVID-19 test kits, is poised to capitalize on the increasing need for rapid testing. This follows the findings of a recent study published by the University of Colorado Boulder and Harvard University, which shows that frequent rapid testing could curb COVID-19 within weeks. “Factors such as turnaround time and frequency are key in limiting the spread of the virus, making rapid tests one of the key tools for managing the virus outbreak,” reads an article on United Medical’s positioning. “As such,” it continues, “the rapid tests are increasingly…

Continue Reading

FridayMar 12, 2021 11:26 am

BioMedNewsBreaks – Brain Scientific Inc.’s (BRSF) Next-Gen NeuroCap EEG Headset Featured in Syndicate Broadcast

Brain Scientific (OTCQB: BRSF) is featured in a broadcast released from NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The new audio press release focuses on the 510(k) clearance the U.S. Food and Drug Administration (“FDA”) has given to Brain Scientific’s next-generation NeuroCap(TM) device. The NeuroCap is an advanced clectroencephalogram (“EEG”) electrode array that obtains rapid EEGs in a variety of settings, from routine clinical and research settings to point of contact, where recording of STAT EEGs is needed. BRSF’s proprietary NeuroCap is a disposable, pre-gelled EEG headset…

Continue Reading

FridayMar 12, 2021 10:39 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Featured in Latest Episode of Bell2Bell Podcast

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) was featured in the The Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. XPhyto Therapeutics’ CEO and Director, Hugh Rogers, joined the latest episode to discuss the company’s recent receipt of its ISO certification and its rapid point-of-care COVID-19 PCR diagnostic test. “We expect to be in the market very soon, within 30 days, pending European approval right now,” Rogers said. “Testing is highly relevant and will be for many years to come. The virus is endemic. It appears that it will…

Continue Reading

ThursdayMar 11, 2021 11:27 am

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Leaders to Present at Upcoming Virtual Investor Summit

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”) has announced that CEO Kirk Huntsman, CFO Brad Amman and investor relations officer Ed Loew are scheduled to present at the Q1 Virtual Investor Summit. Vivos Therapeutics’ presentation is scheduled for 1:30 p.m. ET on March 23, 2021. The presentation will include an overview of the company and other relevant information for potential investors. Formerly MicroCap Conference, the Investor Summit has gained a reputation as an exclusive, independent conference that connects small cap and…

Continue Reading

ThursdayMar 11, 2021 10:23 am

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Preclinical Data Demonstrating Differentiated Mechanism of Action of PH10 from Benzodiazepines

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today announced promising preclinical data for its PH10 drug candidate. The data demonstrate that the potential mechanism of action of PH10, VistaGen’s Phase 2 investigational pherine nasal spray with potential as a rapid-onset, stand-alone treatment for major depressive disorder (“MDD”), does not involve direct activation of GABA-A receptors. This is in distinct contrast to the mechanism of action of benzodiazepines, which act as direct positive modulators of GABA-A receptors. Instead, PH10 is designed to engage receptors in nasal chemosensory neurons,…

Continue Reading

WednesdayMar 10, 2021 12:00 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Leverages ‘Absolute Powerhouse Compound’ as IND Status Paves Way for Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP) CEO John Climaco, in a recent podcast, showed his excitement at news that the U.S. Food and Drug Administration (“FDA”) had granted Berubicin investigational new drug (“IND”) status. The IND designation clears the way for the company to start human clinical trials and to ship the experimental drug across state lines to clinical investigators. “This is the biggest news we’ve announced since our IPO back in November 2019,” Climaco said of the significant milestone. “Based on that IND approval, we expect, in the next 90 to 120 days, we will go from zero active clinical trials…

Continue Reading

WednesdayMar 10, 2021 11:10 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Participation in Emerging Growth Virtual Conference

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, has announced that its CEO James Sapirstein will present at the virtual Maxim Group Emerging Growth Virtual Conference. The two-day conference is slated for March 17–18, 2021. During the online event, all registered attendees will be able to access Sapirstein’s presentation on demand. The presentation will include an overview of AzurRx BioPharma, including its business and clinical-development programs; Sapirstein will also talk about goals and accomplishments the company is working toward in 2021. Following the presentation, Sapirstein and other members of the AzurRx management team will…

Continue Reading

WednesdayMar 10, 2021 9:59 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announced Partner Has Received ISO Certification for Rapid COVID-19 Test

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has announced that 3a-diagnostics GmbH ("3a") has received EN ISO 13485 certification for its rapid point-of-care, SARS-CoV-2 RT-PCR Test System ("Covid-ID Lab"). 3a-diagnostics is XPhyto’s exclusive German diagnostics development partner. In addition the company expects CE-IVD approval for the product this month. These two approvals will allow  3a-diagnostics GmbH to distribute the Covid-ID Lab. The EN ISO approval is the internationally recognized European standard for quality control and management systems in the category of design and manufacture of…

Continue Reading

WednesdayMar 10, 2021 9:01 am

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces FDA 510(k) Application for Exclusive Oral Appliance

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), recently submitted an application to the U.S. Food and Drug Administration (“FDA”) for its mmRNA (“mmRNA”) oral appliance(TM). The 510(k) Class II application focuses on the oral appliance as a treatment for mild-to-moderate OSA, sleep-disordered breathing and snoring in adults. The company’s oral appliance is an updated version of the company’s existing mRNA appliance(R), which previously received FDA clearance as a Class II oral appliance. The company noted that once it received approval for the…

Continue Reading

TuesdayMar 09, 2021 12:46 pm

BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Releases FY 2020 Revenue Results, Year-End Accomplishments

Healthy Extracts (OTCQB: HYEX), a leading developer and manufacturer of heart health, brain health and supplementary technologies, has announced its year-end financial numbers and business updates for the 12-month period ending Dec. 31, 2020. Financial highlights of the report include revenue increases of 71% to $1,276,559 compared to 2019 revenues of $748,377 and a net shareholder equity increase of $3.7 million. In addition, the company eliminated all convertible debt. The report attributes the increases to Healthy Extracts transition to its new business of selling health-nutrition products. Business highlights for the year include a company name change, full reporting and upgrade to…

Continue Reading